Skip to main content

Gazyva

Pronunciation: gaz-ee-vah
Generic name: obinutuzumab
Dosage form: single-dose vial for intravenous infusion (25 mg/mL)
Drug class: CD20 monoclonal antibodies

Medically reviewed by Carmen Pope, BPharm. Last updated on Mar 4, 2025.

What Is Gazyva?

Gazyva (obinutuzumab) is targeted immunotherapy treatment that works with your immune system to treat specific types of blood cancers. Gazyva is a prescription medicine administered intravenously by a healthcare professional, typically alongside other cancer treatments. Currently, no generic version is available.

FDA-Approved Uses for Gazyva

Gazyva is specifically approved for adults with:

Gazyva received FDA approval on November 1, 2013. 

How Gazyva Works

Gazyva targets a protein called CD20 that appears on both normal and cancerous B-lymphocytes (a type of white blood cell). By binding to this protein, Gazyva:

Clinical Effectiveness

Clinical trials have demonstrated that CLL patients receiving Gazyva plus chlorambucil experienced:

Common Side Effects

The most common side effects of Gazyva are:

Serious Side Effects and Warnings

Boxed Warnings

Gazyva carries FDA Boxed Warnings for:

Additional Serious Risks

These are not all the possible side effects of Gazyva. For more information, ask your doctor or pharmacist.

Tell your doctor right away about any side effects you experience. You may report side effects to the FDA at (800) FDA-1088, or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Before receiving Gazyva

Contraindications

Do NOT receive Gazyva if you've had an allergic reaction to obinutuzumab or any ingredients in the injection.

Important Disclosures to Your Doctor

Tell your healthcare provider if you:

Pregnancy and Breastfeeding

Gazyva Administration and Dosing Schedule

Gazyva is administered as an intravenous infusion in a clinic or infusion center. Most people will complete their Gazyva treatment in about 6 months.

Treatment Format

Dosing Schedule

Cycle 1:

Cycles 2-6:

Day 1: 1000 mg

Preparing for Infusions

One Week Before:

Day of the Infusion:

Pre-Medications:

Your doctor may prescribe medications one hour before infusion to reduce side effects:

Ongoing Monitoring

During treatment, your doctor will regularly assess:

What to Avoid During Treatment

Live vaccines: Do not receive BCG, MMR, MMRV, rotavirus, or varicella vaccines during Gazyva treatment

Manufacturer Information

Gazyva is manufactured by Genentech, a subsidiary of Roche. Genentech is headquartered in South San Francisco, California, while Roche's global headquarters is in Basel, Switzerland. Other Notable Medications from Genentech/Roche include:

Gazyva Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for Gazyva.

Gazyva (obinutuzumab) - Genentech, Inc.
Formulation type Strength
Single-Dose Vial 1,000 mg/40 mL (25 mg/mL)

Popular FAQ

What is Gazyva used for and how does it work?

Gazyva is used to treat or delay the progression of chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL). It targets a specific antigen called CD20 on normal and cancerous B-lymphocytes, which signals the immune system to attack and destroy these cells. Stem cells are unaffected because they do not have this antigen. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.